Capsosiphon fulvescens extracts improve obesity-associated metabolic disorders and hepatic steatosis in high-fat diet-induced obese mice

Animal Science Journal

Volumn 89, Issue 3, 2018, Pages 589-596

  Yun, Mi Young ^a   Lee, Jae Sug ^a   Kim, Byoung Soo ^b   Choi, Hwa Jung ^a  

^a Kwangju Women University   (South Korea)

^b Daejeon University   (South Korea)

Author keywords

Capsosiphon fulvescens; hepatic steatosis; high fat diet; metabolic disorders; obesity

Indexed keywords

ADIPONECTIN; LEPTIN; PLANT EXTRACT; SOMATOMEDIN C;

ANIMAL; BLOOD; C57BL MOUSE; CHEMISTRY; FATTY LIVER; GLUCOSE BLOOD LEVEL; GREEN ALGA; LIPID DIET; LIPID METABOLISM; MALE; METABOLIC DISORDER; METABOLISM; OBESITY; PHYTOTHERAPY;

ADIPONECTIN; ANIMALS; BLOOD GLUCOSE; CHLOROPHYTA; DIET, HIGH-FAT; FATTY LIVER; INSULIN-LIKE GROWTH FACTOR I; LEPTIN; LIPID METABOLISM; MALE; METABOLIC DISEASES; MICE, INBRED C57BL; OBESITY; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 85038826240     PISSN: 13443941     EISSN: 17400929     Source Type: Journal    
DOI: 10.1111/asj.12969     Document Type: Article

References (31)

1. Alsanea S, Liu D. 2017. BITC and S-carvone eestrain high-fat diet-induced obesity and ameliorate hepatic steatosis and insulin resistance. Pharmaceutical Research 34, 2241–2249.
2. Bjermo H, Iggman D, Kullberg J, Dahlman I, Johansson L, Persson L, et al. 2012. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. American Journal of Clinical Nutrition 95, 1003–1012.
3. Bouassida A, Zalleg D, Bouassida S, Zaouali M, Feki Y, Zbidi A, et al. 2006. Leptin, its implication in physical exercise and training: a short review. Journal of Sports Science and Medicine 5, 172–181.
4. Bozzetto L, Prinster A, Annuzzi G, Costagliola L, Mangione A, Vitelli A, et al. 2012. Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care 35, 1429–1435.
5. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. 2012. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55, 2005–2023.
6. de Groot S, Gelderblom H, Fiocco M, Bovée JV, van der Hoeven JJ, Pijl H, et al. 2017. Serum levels of IGF-1 and IGF-BP3 are associated with event-free survival in adult Ewing sarcoma patients treated with chemotherapy. OncoTargets and Therapy 10, 2963–2970.
7. Fang Z, Yang Jeong S, Ah Jung H, Sue Choi J, Sun Min B, Hee Woo M. 2012. Capsofulvesins A-C, cholinesterase inhibitors from Capsosiphon fulvescens. Chemical and Pharmaceutical Bulletin (Tokyo) 60, 1351–1358.
8. Gao BZ, Chen JC, Liao LH, Xu JQ, Lin XF, Ding SS. 2015. Erchen decoction prevents high-fat diet induced metabolic disorders in C57BL/6 mice. Evidence-Based Complementary and Alternative Medicine 2015, 501272.
9. Gu M, Zhang Y, Fan S, Ding X, Ji G, Huang C. 2013. Extracts of Rhizoma polygonati odorati prevent high-fat diet-induced metabolic disorders in C57BL/6 mice. PLoS ONE 8, e81724.
10. Hammond RA, Levine R. 2010. The economic impact of obesity in the United States. Diabetes, Metabolic Syndrome and Obesity 3, 285–295.
11. Haufe S, Engeli S, Kast P, Böhnke J, Utz W, Haas V, et al. 2011. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology 53, 1504–1514.
12. Hu E, Liang P, Spiegelman BM. 1996. AdipoQ is a novel adipose-specific gene dysregulated in obesity. The Journal of Biological Chemistry 271, 10697–10703.
13. Jacob S, Machann J, Rett K, Brechtel K, Volk A, Renn W, et al. 1999. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 48, 1113–1119.
14. Ji W, Zhao M, Wang M, Yan W, Liu Y, Ren S, et al. 2017. Effects of canagliflozin on weight loss in high-fat diet-induced obese mice. PLoS ONE 12, e0179960.
15. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. 2006. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. Journal of Clinical Investigation 116, 1784–1792.
16. Karnjanapratum S, Tabarsa M, Cho M, You S. 2012. Characterization and immunomodulatory activities of sulfated polysaccharides from Capsosiphon fulvescens. International Journal of Biological Macromolecules 51, 720–729.
17. Kim EY, Choi YH, Lee JI, Kim IH, Nam TJ. 2015. Antioxidant activity of oxygen evolving enhancer protein 1 purified from Capsosiphon fulvescens. Journal of Food Science 80, H1412–H1417.
18. Loomba R, Sanyal AJ. 2013. The global NAFLD epidemic. Nature Reviews Gastroenterology & Hepatology 10, 686–690.
19. Luo Y, Burrington CM, Graff EC, Zhang J, Judd RL, Suksaranjit P, et al. 2015. Metabolic phenotype and adipose and liver features in a high-fat Western diet-induced mouse model of obesity-linked NAFLD. American Journal of Physiology – Endocrinology and Metabolism 310, 418–439.
20. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. 1996. cDNA cloning and expression of a novel adipose specific collagenlike factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochemical and Biophysical Research Communications 221, 286–296.
21. Padwal RS, Majumdar SR. 2007. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. The Lancet 369, 71–77.
22. Palacios-Martinez D, Garcia-Alvarez JC, Montero-Santamaria N, Villar-Ruiz OP, Ruiz-Garcia A, Diaz-Alonso RA. 2013. Macrocytic anemia and thrombocytopenia induced by orlistat. International Journal of, Endocrinology and Metabolism 11, e6721.
23. Peters HPF, Schrauwen P, Verhoef P, Byrne CD, Mela DJ, Pfeiffer AFH, et al. 2017. Liver fat: a relevant target for dietary intervention? Summary of a Unilever workshop. Journal of Nutritional Science 6, e15.
24. Pi-Sunyer X. 2010. The medical risks of obesity. Postgraduate Medicine 121, 21–33.
25. Pollak MN, Schernhammer ES, Hankinson SE. 2004. Insulinlike growth factors and neoplasia. Nature Reviews Cancer 4, 505–518.
26. Synytsya A, Choi DJ, Pohl R, Na YS, Capek P, Lattová E, et al. 2015. Structural features and anti-coagulant activity of the sulphated polysaccharide SPS-CF from a green Alga Capsosiphon fulvescens. Marine Biotechnology (NY) 17, 718–735.
27. Vinolo MA, Rodrigues HG, Festuccia WT, Crisma AR, Alves VS, Martins AR, et al. 2012. Tributyrin attenuates obesity-associated inflammation and insulin resistance in high-fat-fed mice. American Journal of Physiology – Endocrinology and Metabolism 303, 272–282.
28. Yoshioka H, Mori M, Fujii H, Nonogaki T. 2017. Sasa veitchii extract reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet. Nagoya Journal Medical Science 79, 279–290.
29. Yu H, Rohan T. 2000. Role of the insulin-like growth factor family in cancer development and progression. Journal of the National Cancer Institute 92, 1472–1489.
30. Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, et al. 2006. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor–deficient mice. Diabetes 55, 2180–2191.
31. Zhang M, Hu T, Zhang S, Zhou L. 2015. Associations of different adipose tissue depots with insulin resistance: a systematic review and meta-analysis of observational studies. Scientific Reports 21, 18495.